Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod Add-on to PPIs in GERD
NCT00171483Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Tegaserod + PPI with Placebo + PPI (2 arms). Primary endpoint: Effect of tegaserod in addition to proton pump inhibitors on heartburn and regurgitation at 6 weeks. Started Jan 2004; status: completed.
02
Drugs
tegaserod
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00171483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171483.